Inder Kaul News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Impressive New Data on Novel Schizophrenia Hopeful KarXT

Impressive New Data on Novel Schizophrenia Hopeful KarXT
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUniversity of maryland school medicineInder kaulBristol myers squibbRobert buchananChristophu correllDrug administrationMaryland psychiatric research centerZucker school of medicine at hofstra northwellKaruna therapeuticsZucker schoolNew york cityMedscape medicalNegative syndrome scaleDecision expected this

Positive Phase 3 Results for New Antipsychotic in Psychosis

The investigational antipsychotic KarXT is effective in reducing positive and negative symptoms of schizophrenia, with a favorable side-effect profile in the pivotal EMERGENT-2 trial.

United kingdomNew yorkUnited statesMclean hospitalAnn shinnInder kaulAndrea ciprianiBipolar disorder research programDepartment of psychiatryHarvard medical schoolDrug administrationIcahn school of medicine at mount sinaiUniversity of oxfordKaruna therapeuticsPrescription drug user fee actNegative syndrome scale

Peer-Reviewed EMERGENT-2 Trial Data Supports Xanomeline-Trospium for Schizophrenia

In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group.

United statesInder kaulDrug administrationSegal trialsRishi kakarKaruna therapeuticsNew drug applicationNegative syndrome scaleSafety of the muscarinic receptor agonistThe united statesResults fromFlexible dose phaseXanomeline trospium drug application

Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

BOSTON (BUSINESS WIRE) Dec 14, 2023

United statesJulie ciardielloSteve paulAlexis smithInder kaulExchange commissionSecurities exchangeKaruna therapeutics incKaruna therapeuticsNegative syndrome scaleClinical global impression severityRishi kakarSegal trialsSecurities actSecurities exchange actAnnual report

Karuna Therapeutics Inc (KRTX) Reports Publication of Phase 3 EMERGENT-2 Trial Data on KarXT

Karuna Therapeutics Inc (KRTX) Reports Publication of Phase 3 EMERGENT-2 Trial Data on KarXT
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesInder kaulSteve paulKaruna therapeutics incKaruna therapeuticsLancet theNegative syndrome scaleClinical global impression severityRishi kakarSegal trials